ClinicalTrials.gg

Program

Etoricoxib

Also written as “etoricoxib”, “MK0663, etoricoxib” and “MK0663, Arcoxia, etoricoxib / Duration of Treatment: 3 Days”.

Its studies are mostly in Osteoarthritis · Pain · Low Back Pain · Acute Pain · Dysmenorrhea, led by 7 companies.

Furthest: phase 4, since Aug 25, 200434 company-led studies, 1 open or runningNext primary completion: Dec 31, 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Organon230 open or runningphase 4since Aug 25, 2004Aug 25, 2004none ahead
Laboratorios Silanes S.A. de C.V.61 open or runningphase 3since Jul 13, 2021Jul 13, 2021Dec 31, 2026phase 3 · NCT06863701
Analgesic Solutions10 open or runningphase 4since Dec 20, 2010Dec 20, 2010none ahead
Dexa Medica Group10 open or runningno phasesince Jan 30, 2018Jan 30, 2018none ahead
Laboratorios Liomont10 open or runningphase 3since Apr 15, 2026Apr 15, 2026none ahead
Pharmtechnology10 open or runningphase 1since Mar 31, 2021Mar 31, 2021none ahead
X-pert Med10 open or runningphase 1since Jan 5, 2011Jan 5, 2011none ahead

Also a collaborator on its studies: epic-research-cro, pt-equilab-international and Merck.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 19 studies since Aug 25, 2004.

  1. Dec 20, 2010Analgesic Solutions's first study: phase 4 study in Neuralgia, PostherpeticNew to Analgesic SolutionsAnalgesic Solutions · NCT01264237 · 120 enrolled · United Kingdom
  2. Jan 5, 2011X-pert Med's first study: phase 1 study in MyalgiaNew to X-pert MedX-pert Med · NCT01271348 · 50 enrolled · Germany
  3. Sep 2, 2011Phase 4 study in OsteoarthritisOrganon · NCT01429168
  4. Oct 27, 2011Phase 3 study in DysmenorrheaOrganon · NCT01462370 · 139 enrolled
  5. Mar 12, 2012Phase 3 study in Osteoarthritis, KneeOrganon · NCT01554163 · 239 enrolled
  6. Nov 5, 2013Phase 2 study in Osteoarthritis PainOrganon · NCT01980940 · 70 enrolled
  7. Jan 30, 2018Dexa Medica Group's first study: no phase study in HealthyNew to Dexa Medica GroupDexa Medica Group · NCT03422575 · 26 enrolled · Indonesia
  8. Mar 31, 2021Pharmtechnology's first study: phase 1 study in BioequivalenceNew to PharmtechnologyPharmtechnology · NCT04830579 · 34 enrolled · Russian Federation
  9. Jul 13, 2021Laboratorios Silanes S.A. de C.V.'s first study: phase 3 study in Back PainNew to Laboratorios Silanes S.A. de C.V.Laboratorios Silanes S.A. de C.V. · NCT04968158 · 124 enrolled · Mexico
  10. Sep 6, 2022Phase 1 study in PainLaboratorios Silanes S.A. de C.V. · NCT05533073 · 42 enrolled · Mexico
  11. Jul 18, 2024Phase 3 study in Acute PainLaboratorios Silanes S.A. de C.V. · NCT06517823 · 190 enrolled · Mexico
  12. Mar 3, 20252 phase 3 studiesLaboratorios Silanes S.A. de C.V. · NCT06863701, NCT06863662
  13. Dec 28, 2025Phase 3 study in BursitisLaboratorios Silanes S.A. de C.V. · NCT07328022 · 89 enrolled · Mexico
  14. Apr 15, 2026Laboratorios Liomont's first study: phase 3 study in AgnosiaNew to Laboratorios LiomontLaboratorios Liomont · NCT07549386 · 123 enrolled · Mexico

Ahead

  1. Dec 31, 2026Primary completion: phase 3 study in Arthritis, GoutyLaboratorios Silanes S.A. de C.V. · NCT06863701

TargetBeta

PTGS2 →read by rule
“Cyclooxygenase-2 inhibitor”ChEMBL 37, by rule

Other programs on PTGS2

ProgramCompanyFurthest phaseStudies
AcetaminophenruleJohnson & Johnsonphase 4136
IbuprofenrulePfizerphase 4113
AspirinruleBayerphase 484
CelecoxibruleViatrisphase 478
MeloxicamruleBoehringer Ingelheimphase 467
dexketoprofenruleMenarini Groupphase 48
SulfasalazineruleBristol-Myers Squibbphase 47
dexibuprofenruleaponia-laboratories-incphase 46
BenzydamineruleAngelini Pharmaphase 44
DipyroneruleHypera Pharmaphase 44
PiroxicamruleTaisho Pharmaceuticalphase 44
FlurbiprofenruleGlaxoSmithKlinephase 312

Studies

All 34 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07549386Agnosia · Mexico3CompletedLaboratorios LiomontMar 27, 2025123
NCT07328022Bursitis · Mexico3CompletedLaboratorios Silanes S.A. de C.V.Aug 20, 202589
NCT06863701Arthritis, Gouty · Mexico3RecruitingLaboratorios Silanes S.A. de C.V.Dec 31, 202672
NCT06863662Spasm · Mexico3CompletedLaboratorios Silanes S.A. de C.V.Sep 26, 2025136
NCT06517823Acute Pain · Mexico3CompletedLaboratorios Silanes S.A. de C.V.Oct 4, 2024190
NCT05533073Pain · Mexico1CompletedLaboratorios Silanes S.A. de C.V.Sep 7, 202042
NCT04968158Back Pain · Mexico3CompletedLaboratorios Silanes S.A. de C.V.Mar 15, 2022124
NCT04830579Bioequivalence · Russian Federation1UNKNOWNPharmtechnologyApr 28, 202134
NCT03422575Healthy · Indonesia–CompletedDexa Medica GroupDec 201526
NCT01980940Osteoarthritis Pain2CompletedOrganonNov 26, 201470
NCT01554163Osteoarthritis, Knee3CompletedOrganonMar 2013239
NCT01462370Dysmenorrhea3CompletedOrganonJun 2012139
NCT01429168Osteoarthritis4WithdrawnOrganonAug 20120
NCT01271348Myalgia · Germany1CompletedX-pert MedOct 201150
NCT01264237Neuralgia, Postherpetic · United Kingdom4UNKNOWNAnalgesic SolutionsAug 2011120
NCT01208207Spondylitis, Ankylosing3CompletedOrganonNov 12, 20141,015
NCT01208181Arthritis, Rheumatoid3CompletedOrganonJun 9, 20141,404
NCT00820027Pain, Postoperative3CompletedOrganonDec 13, 2010776
NCT00788710Acute Pain Following a Total Abdominal Hysterectomy3CompletedOrganonJul 2010430
NCT00757627Pain4CompletedOrganonDec 2008500
NCT00694369Postoperative Dental Pain3CompletedOrganonDec 2008588
NCT00393354Low Back Pain3CompletedOrganonNov 2000325
NCT00393211Low Back Pain3CompletedOrganonNov 2000319
NCT00380627Pain4CompletedOrganonJan 31, 2006337
NCT00380523Pain4CompletedOrganonMay 2005237
NCT00269191Osteoarthritis3CompletedOrganonNov 7, 2003528
NCT00264147Arthritis, Rheumatoid2CompletedOrganonMar 2008761
NCT00242489Osteoarthritis2CompletedOrganonFeb 19991,167
NCT00095017Bone Neoplasms2WithdrawnOrganon0
NCT00092781Osteoarthritis3CompletedOrganonFeb 1, 2005500
NCT00092768Osteoarthritis3CompletedOrganonFeb 1, 2005500
NCT00092755Osteoarthritis3CompletedOrganonNov 13, 2003548
NCT00092729Dysmenorrhea3CompletedOrganonDec 6, 2002129
NCT00090181Chronic Low Back Pain4CompletedOrganonMar 2005401

How it is read

Names in the registry

  • “etoricoxib”, 7 entries
  • “Etoricoxib”, 4 entries
  • “MK0663, etoricoxib”, 3 entries
  • “MK0663, Arcoxia, etoricoxib / Duration of Treatment: 3 Days”, 2 entries
  • “Etoricoxib 90 mg”, 2 entries

Codes read as this program: MK0663.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.